Symbiotec Pharmalab Ltd. IPO Details

Symbiotec Pharmalab Ltd. IPO Details

MainboardUpcoming
Min. Investment
₹14,820
/ 15 Shares
Issue Price
₹938 to ₹988
Subscription
-
Issue Size
₹1757.00 Cr
Lot Size
15 Shares
Open
2026-08-24
Close
2026-08-27
Allotment
2026-08-28
Listing
2026-09-01

1. Symbiotec Pharmalab Ltd. IPO Details (Mainboard) IPO Details

Symbiotec Pharmalab Ltd IPO is a mainboard book-built issue aggregating up to ₹2,180.00 crores. The issue comprises a fresh issue of shares worth up to ₹150.00 crores and an Offer for Sale (OFS) of up to ₹2,030.00 crores by existing promoters and private equity investors (including Satwani Holdings LLP, Rosewood Investments, and India Business Excellence Fund-III).
The IPO received SEBI approval in March 2026. The specific bidding dates, allotment timeline, and tentative listing dates on the BSE and NSE mainboard platforms will be finalized upon release of the Red Herring Prospectus (RHP).
The price band and minimum application lot size for retail and HNI investors are currently To Be Announced (TBA).

Grey Market Premium

Estimated listing gains (Live)

+₹409Per Share
EST. GAINS
Updated real-time from market sources

Symbiotec Pharmalab IPO Details

IPO DateTo be announced
Listing DateTo be announced
Face ValueTo be announced
Price BandTo be announced
Lot SizeTo be announced
Sale TypeFresh issue cum OFS
Issue TypeBookbuilding IPO
Listing AtBSE, NSE
Total Issue SizeAgg. up to ₹2,180 Cr
Fresh IssueAgg. up to ₹150 Cr
Offer for SaleAgg. up to ₹2,030 Cr

IPO Lead Managers & Registrar

RoleEntity Name
RegistrarMUFG Intime India Pvt.Ltd.
Book Running Lead ManagerJM Financial Ltd.

2. About Symbiotec Pharmalab Ltd. IPO Details (Mainboard)

Incorporated in 2002 and headquartered in Indore, Madhya Pradesh, Symbiotec Pharmalab Limited is a research and development-driven pharmaceutical and biotechnology company. The company specializes in the development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs), active steroid and hormone-based APIs, and complex intermediates. Operating two industrial-scale manufacturing facilities, it holds regulatory approvals from global authorities including the US FDA, EU-GMP, and Korea's MFDS, exporting to over 40 countries across regulated and emerging markets.

Track Record (Financial Highlights)

  • Financial Scale: Operational revenue grew from ₹572.97 Cr in FY23 to ₹723.33 Cr in FY24, and reached ₹755.98 Cr for the fiscal year ended March 31, 2025.
  • Profitability: Net profit (PAT) stood at ₹23.49 Cr in FY23, ₹100.06 Cr in FY24, and ₹96.79 Cr in FY25.
  • EBITDA & Net Worth: EBITDA expanded to ₹206.11 Cr in FY25 from ₹177.04 Cr in FY24, while Net Worth expanded to ₹821.15 Cr.

Symbiotec Pharmalab Ltd IPO GMP

As of August 18, 2026, the Grey Market Premium (GMP) is currently ₹0.
Note: Grey market tracking indicators remain unquoted ahead of the official price band and bidding window announcements.

Symbiotec Pharmalab Ltd IPO Allotment Status

The allotment schedule will be finalized shortly after the bidding window closes.
Check Symbiotec Pharmalab Allotment Status
To check your status online once the issue opens and closes, visit the assigned registrar tracking portal or monitor updates on the NSE and BSE mainboard portals:
MUFG Intime India IPO Status Portal
You can verify your status via:
  • Registrar's website (MUFG Intime India Private Limited)
  • BSE & NSE official mainboard IPO tracking portals
  • Using your PAN number, Application ID, or DP ID/Client ID

Strengths

  • Global Niche Leadership: Holds a significant global market share (36–44%) in specialized steroid and hormone-based APIs.
  • High Regulatory Barriers: Multi-facility industrial platform backed by global regulatory approvals (US FDA, EU-GMP) ensuring long-standing relationships with global pharma majors.
  • R&D and Backward Integration: Integrated capabilities across organic chemistry, biotechnology, complex injectables, and fermentation.

Weaknesses

  • Product Concentration Risk: Almost 100% of operational revenue is derived from the sale of APIs, with high dependency on steroid and hormone product segments.
  • Top Customer Concentration: Revenue generated from top ten customers accounts for over 55–60% of total product sales.
  • Regulatory & Hazardous Material Compliance: Manufacturing involves hazardous chemical synthesis and biological processes subject to stringent environmental and health safety regulations.

How the Company Will Use IPO Money

The fresh issue proceeds (₹150.00 Cr) will be utilized for:
  • Debt Repayment: Prepayment or partial/full repayment of certain outstanding borrowings availed by the company.
  • Working Capital Requirements: Funding operational working capital requirements.
  • General Corporate Purposes: Meeting general corporate administrative and operational overheads.

Lead Manager & Registrar

  • Book Running Lead Managers: JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited, Nomura Financial Advisory & Securities (India) Pvt Ltd
  • Registrar: MUFG Intime India Private Limited

Frequently Asked Questions (Symbiotec Pharmalab Ltd. IPO Details)

D
Founder | India IPO Updates

DIPAK DANGODARA

I am the founder of India IPO Updates, a platform dedicated to tracking the Indian IPO market since 2024. With a background in digital research and data analysis, I built this platform to simplify IPO tracking covering issue details, live Grey Market Premium (GMP), subscription status, and allotment updates sourced from public exchange data and verified market sources.

I am not an SEBI-registered investment advisor. All GMP and market data shared here is for informational purposes only and should not be considered investment advice. Investors are advised to consult a registered financial advisor before making investment decisions.